Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension

European Respiratory Journal

Volumn 23, Issue 2, 2004, Pages 321-326

  Ghofrani, H Ardeschir ^a   Friese, G ^a   Discher, T ^a   Olschewski, H ^a   Schermuly, R T ^a   Weissmann, N ^a   Seeger, W ^a   Grimminger, F ^a   Lohmeyer, J ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Acquired immune deficiency; Human immunodeficiency virus; Iloprost; Inhalation; Pulmonary hypertension; Syndrome; Treatment

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; BOSENTAN; DIDANOSINE; EFAVIRENZ; FUROSEMIDE; HYDROXYUREA; ILOPROST; INDINAVIR; LAMIVUDINE; NELFINAVIR; NITRIC OXIDE; OXYGEN; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; RITONAVIR; SAQUINAVIR; SILDENAFIL; SPIRONOLACTONE; STAVUDINE; ZIDOVUDINE;

ADULT; AEROSOL; ARTERY CATHETERIZATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FEMALE; FEMORAL ARTERY; HEART CATHETERIZATION; HEART INDEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; LONG TERM CARE; LUNG VASCULAR RESISTANCE; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SIDE EFFECT; STATISTICAL ANALYSIS; VASODILATATION; VENOUS OXYGEN TENSION; WALKING;

ADMINISTRATION, INHALATION; ADULT; COMBINED MODALITY THERAPY; FEMALE; HEART CATHETERIZATION; HIV INFECTIONS; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; LONG-TERM CARE; MALE; MIDDLE AGED; NITRIC OXIDE; OXYGEN INHALATION THERAPY; PULMONARY ARTERY; PULMONARY WEDGE PRESSURE; STROKE VOLUME; TREATMENT OUTCOME; VASCULAR RESISTANCE; VASODILATOR AGENTS;

EID: 1042263812     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.03.00057703     Document Type: Article

References (28)

1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-117.
2. Mette SA, Palevsky HI, Pietra GG, et al. Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. Am Rev Respir Dis 1992; 145: 1196-1200.
3. Petitpretz P, Brenot F, Azarian R, et al. Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. Circulation 1994; 89: 2722-2727.
4. Opravil M, Pechere M, Speich R, et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 1997: 155: 990-995.
5. Rich S, ed. Primary Pulmonary Hypertension. Executive Summary from the World Symposium on Primary Pulmonary Hypertension 1998, Evian, France, 6-10 September 1998. www.who.int/cardiovascular÷seases/resources/publications/en/ Date accessed: 10 November 2003.
6. Cooper DA. Immunological effects of antiretroviral therapy. Antivir Ther 1998; 3: Suppl. 4, 19-23.
7. Bower M, Fox P, Fife K, Gill J, Nelson M, Gazzard B. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS 1999; 13: 2105-2111.
8. McNaghten AD, Hanson DL, Jones JL, Dworkin MS, Ward JW. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. Adult/Adolescent Spectrum of Disease Group. AIDS 1999; 13: 1687-1695.
9. Nunes H, Humbert M, Sitbon O, et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003; 167: 1433-1439.
10. Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 2000; 162: 1846-1850.
11. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296-302.
12. Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996; 124: 820-824.
13. Olschewski H, Ghofrani HA, Schmehl T, et al. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med 2000; 132: 435-443.
14. Stricker H, Domenighetti G, Fiori G, Mombelli G. Sustained improvement of performance and haemodynamics with long-term aerosolised prostacyclin therapy in severe pulmonary hypertension. Schweiz Med Wochenschr 1999; 129: 923-927.
15. Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000; 342: 1866-1870.
16. Beghetti M, Berner M, Rimensberger PC. Long term inhalation of iloprost in a child with primary pulmonary hypertension: an alternative to continuous infusion. Heart 2001; 86: E10.
17. Gessler T, Schmehl T, Hoeper MM, et al. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. Eur Respir J 2001; 17: 14-19.
18. Speich R, Jenni R, Opravil M, Pfab M, Russi EW. Primary pulmonary hypertension in HIV infection. Chest 1991; 100: 1268-1271.
19. Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA. HIV-related pulmonary hypertension: analytic review of 131 cases. Chest 2000; 118: 1133-1141.
20. Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993; 328: 399-405.
21. Sitbon O, Brenot F, Denjean A, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 1995; 151: 384-389.
22. Sitbon O, Humbert M, Jagot JL, el al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998; 12: 265-270.
23. Hoeper MM, Olschewski H, Ghofrani HA, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol 2000; 35: 176-182.
24. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994: 121: 409-415.
25. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322-329.
26. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
27. Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002; 39: 1496-1502.
28. Schumacher YO, Zdebik A, Huonker M, Kreisel W. Sildenafil in HIV-related pulmonary hypertension. AIDS 2001; 15: 1747-1748.